EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of real-world clinical and pathological differences between HER2-0 and HER2-low localized breast cancer

Milla Hollmén, Eliisa Löyttyniemi, Eeva Juhanoja, Pia Vihinen, Maria Sundvall

Cancer Treatment and Research Communications · 2026 · 47 · 101204

DOI: 10.1016/j.ctarc.2026.101204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Milla Hollmén und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and FICAN West Cancer Center, Turku University Hospital and University of Turku, Turku, Finland; Doctoral Program in Clinical …. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Turku University Foundation, Lounais-Suomen Syöpäyhdistys, Turun Yliopisto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsHumansFemaleRetrospective StudiesMiddle AgedAgedAdultImmunohistochemistryBiomarkers, TumorPrognosisFinland

Stichwörter der Autor:innen

Breast cancerClinicopathologic featuresHER2HER2-lowPrognosisReal-world dataSurvival

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology and FICAN West Cancer Center, Turku University Hospital and University of Turku, Turku, Finland; Doctoral Program in Clinical Research, University of Turku, Turku, Finland. Electronic address: mil…
  • Department of Biostatistics, University of Turku and Turku University Hospital, Turku, Finland.
  • Department of Oncology and FICAN West Cancer Center, Turku University Hospital and University of Turku, Turku, Finland.
  • Department of Oncology and FICAN West Cancer Center, Turku University Hospital and University of Turku, Turku, Finland; Cancer Research Unit, Institute of Biomedicine, University of Turku, Turku, Finland.

Förderung

  • Turku University Foundation
  • Lounais-Suomen Syöpäyhdistys
  • Turun Yliopisto
  • Finnish Medical Foundation

Zitieren

APA

Hollmén, M., Löyttyniemi, E., Juhanoja, E., Vihinen, P., & Sundvall, M. (2026). Characterization of real-world clinical and pathological differences between HER2-0 and HER2-low localized breast cancer. Cancer Treatment and Research Communications, 47, 101204. https://doi.org/10.1016/j.ctarc.2026.101204

Vancouver

Hollmén M, Löyttyniemi E, Juhanoja E, Vihinen P, Sundvall M. Characterization of real-world clinical and pathological differences between HER2-0 and HER2-low localized breast cancer. Cancer Treatment and Research Communications. 2026;47:101204. doi:10.1016/j.ctarc.2026.101204

BibTeX
@article{Hollmn2026,
  author = {Hollmén, Milla and Löyttyniemi, Eliisa and Juhanoja, Eeva and Vihinen, Pia and Sundvall, Maria},
  title = {Characterization of real-world clinical and pathological differences between HER2-0 and HER2-low localized breast cancer},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {47},
  pages = {101204},
  doi = {10.1016/j.ctarc.2026.101204}
}
Kostenlos starten →